Unknown

Dataset Information

Regulatory efforts to address the access gap for foreign new drugs in China: the priority review program and related policies.


ABSTRACT:

Background

China has implemented the priority review (PR) program and flexible registration requirements for new drugs with significant clinical value since 2016 to accelerate drug access. We aim to explore the impact of the reform efforts on the drug access gap between China and the US.

Methods

We collected data on the imported new drug approvals that were licensed in China between 2007 and 2023, and measured their launch delays as compared to the US. Difference-in-difference models were used to compare the launch delays of PR approvals and non-PR approvals before and after the implementation of the PR. Propensity score matching was used to construct the imputed PR and non-PR approvals in the pre-PR period.

Results

A total of 410 imported approvals were licensed in C

SUBMITTER: Zhu X 

PROVIDER: S-EPMC11853587 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature